When to stop immunotherapy for advanced melanoma: the emulated target trials.

Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years.

[Therapeutic revolutions against melanoma].

THERAPEUTIC REVOLUTIONS AGAINST MELANOMA. Responsible for 90% of skin cancer deaths, melanoma is the most aggressive skin tumor. Although the main risk factor is known, its incidence doubles every 10 years.